Clinical trial
Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With…
NCT00125827 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00125827 |
|---|---|
| Title | Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors |
| Official title | A Phase I Dose Escalation and Pharmacokinetic Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors |
| Intervention type | Drug |
| Interventions | clofarabine (oral formulation) |
| Enrollment | 24 |
| Start date | Oct 1, 2003 |
| Primary completion | Oct 1, 2004 |
| Completion | Feb 1, 2006 |
| First posted | Aug 2, 2005 |
| Last update posted | Mar 19, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: